Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Zarantonelli L et al. | Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. | 1999 | Antimicrob. Agents Chemother. | pmid:10508026 |
Jackson LA et al. | Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease. | 1999 | J. Antimicrob. Chemother. | pmid:10511413 |
Yoh M et al. | Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. | 1999 | Can. J. Microbiol. | pmid:10526400 |
Melnichouk S et al. | Evaluation of lansoprazole (an H+/K+-ATPase inhibitor) and azithromycin (an antibiotic) for control of gastric ulceration in swine during periods of feed deprivation. | 1999 | Can. J. Vet. Res. | pmid:10534003 |
Howell MR et al. | Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. | 1999 | Sex Transm Dis | pmid:10534206 |
Mabey D and Bailey R | Eradication of trachoma worldwide. | 1999 | Br J Ophthalmol | pmid:10535853 |
Muhlestein JB | Animal models of chlamydia and atherosclerosis. | 1999 | Am. Heart J. | pmid:10539862 |
Gupta S | Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease. | 1999 | Am. Heart J. | pmid:10539869 |
Dunne M | WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. | 1999 | Am. Heart J. | pmid:10539870 |
Grayston JT | Design of future intervention studies for Chlamydia pneumoniae in atherosclerosis. | 1999 | Am. Heart J. | pmid:10539875 |
Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
Watt G et al. | Azithromycin activities against Orientia tsutsugamushi strains isolated in cases of scrub typhus in Northern Thailand. | 1999 | Antimicrob. Agents Chemother. | pmid:10543774 |
Ghaffar F et al. | Increased carriage of resistant non-pneumococcal alpha-hemolytic streptococci after antibiotic therapy. | 1999 | J. Pediatr. | pmid:10547251 |
Fong IW et al. | Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? | 1999 | Clin. Diagn. Lab. Immunol. | pmid:10548582 |
[Short-term therapy with Azithromycin. Pneumonia-pathogens, most commonly encountered in practice, easily targeted]. | 1999 | Internist (Berl) | pmid:10549000 | |
Whitty CJ et al. | Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. | 1999 | Pediatr. Infect. Dis. J. | pmid:10571428 |
Tan HH and Chan RK | An open label comparative study of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in males and Chlamydia trachomatis cervicitis in female sex workers in an STD clinic in Singapore. | 1999 | Singapore Med J | pmid:10572491 |
Chern KC et al. | Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. | 1999 | Br J Ophthalmol | pmid:10574809 |
Paavonen J and Eggert-Kruse W | Chlamydia trachomatis: impact on human reproduction. | 1999 Sep-Oct | Hum. Reprod. Update | pmid:10582782 |
Koletar SL et al. | Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. | 1999 | Antimicrob. Agents Chemother. | pmid:10582873 |